Thirteen relapsed or refractory AML patients were treated with the FLA regimen. A complete remission was observed in 54% of cases but the median duration of remission was short (4 months). These results suggest that the FLA regimen is not able to induce a durable complete remission in the poor-risk AML patients.
Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia.
ZAJA, Francesco
1998-01-01
Abstract
Thirteen relapsed or refractory AML patients were treated with the FLA regimen. A complete remission was observed in 54% of cases but the median duration of remission was short (4 months). These results suggest that the FLA regimen is not able to induce a durable complete remission in the poor-risk AML patients.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Russo_Fludarabine_Haematologica_1998.pdf
non disponibili
Tipologia:
Altro materiale allegato
Licenza:
Non pubblico
Dimensione
159.67 kB
Formato
Adobe PDF
|
159.67 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
